Genmab A/S

Genmab A/S Equity

The The Equity of Genmab A/S (GMAB.CO) as of Sep 27, 2026 is 895.69 M USD. In the previous year, The Equity was 5.63 B USD — a change of -84.10% (lower).

Equity

895.69 MUSD

YoY

-84.10%

Last updated:

In 2026, Genmab A/S's equity was 895.69 M USD, a -84.10% increase from the 5.63 B USD equity in the previous year.

The Genmab A/S Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.23 B USD
Jan 1, 2019
2.16 B USD
Jan 1, 2020
2.94 B USD
Jan 1, 2021
3.41 B USD
Jan 1, 2022
4.19 B USD
Jan 1, 2023
4.85 B USD
Jan 1, 2024
5.63 B USD
Jan 1, 2025
895.69 M USD
The Genmab A/S Equity history
YEAREquityYoY
895.69 MUSD-84.10%
5.63 BUSD+16.09%
4.85 BUSD+15.86%
4.19 BUSD+22.91%
3.41 BUSD+16.08%
2.94 BUSD+36.11%
2.16 BUSD+75.29%
1.23 BUSD+27.78%
962.92 MUSD+29.95%
741.01 MUSD+38.43%
535.29 MUSD+71.51%
312.10 MUSD—
Access this data via the Eulerpool API
Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Genmab A/S's Equity

Genmab A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Genmab A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Genmab A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Genmab A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Genmab A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Genmab A/S stock

The Equity of Genmab A/S is 895.69 M USD in 2026.

The Equity of Genmab A/S changed from 5.63 B USD to 895.69 M USD, representing a -84.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Genmab A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Genmab A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Genmab A/S